ATP Life Science Ventures, L.P. - Q4 2020 holdings

$1.3 Billion is the total value of ATP Life Science Ventures, L.P.'s 3 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 50.0% .

 Value Shares↓ Weighting
STOK BuyStoke Therapeutics, Inc.$1,062,825,000
+89.1%
17,161,713
+2.2%
82.06%
+8.3%
AKRO  Akero Therapeutics, Inc.$168,435,000
-6.2%
5,830,2030.0%13.00%
-46.3%
KDNY NewChinook Therapeutics, Inc.$63,859,0004,028,937
+100.0%
4.93%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-03
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Stoke Therapeutics, Inc.6Q1 202182.1%
Akero Therapeutics, Inc.6Q1 202125.6%
None3Q4 20210.0%
Chinook Therapeutics, Inc.2Q1 20217.0%

View ATP Life Science Ventures, L.P.'s complete holdings history.

Latest significant ownerships (13-D/G)
ATP Life Science Ventures, L.P. Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHINOOK THERAPEUTICS, INC.Sold outJanuary 21, 202200.0%
Akero Therapeutics, Inc.June 29, 202137,5550.1%
Stoke Therapeutics, Inc.June 29, 202136,9430.1%
Akero Therapeutics, Inc.July 14, 20205,830,20317.2%
Cerecor Inc.February 12, 2016595,4366.9%
Dermira, Inc.February 12, 2016? ?

View ATP Life Science Ventures, L.P.'s complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2022-01-21
SC 13G/A2022-01-21
13F-HR2021-10-20
13F-HR2021-08-04
42021-06-30
42021-06-30
SC 13D/A2021-06-29
SC 13D/A2021-06-29
13F-HR2021-05-12
13F-HR2021-02-03

View ATP Life Science Ventures, L.P.'s complete filings history.

Compare quarters

Export ATP Life Science Ventures, L.P.'s holdings